In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16 Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20 Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A)
palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B)
6- and 12-month survival probabilities